{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:13:59Z","timestamp":1775841239585,"version":"3.50.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Granulocyte colony stimulating factor (GCSF) can decrease mortality of patients undergo chemotherapy through increasing neutrophil counts. Many strategies have been developed to improve its blood circulating time. Albumin binding domain (ABD) was genetically fused to N-terminal end of GCSF encoding sequence and expressed as cytoplasmic inclusion bodies within <jats:italic>Escherichia coli<\/jats:italic>. Biological activity of ABD-GCSF protein was assessed by proliferation assay on NFS-60 cells. Physicochemical properties were analyzed through size exclusion chromatography, circular dichroism, intrinsic fluorescence spectroscopy and dynamic light scattering. Pharmacodynamics and pharmacokinetic properties were also investigated in a neutropenic rat model. CD and IFS spectra revealed that ABD fusion to GCSF did not significantly affect the secondary and tertiary structures of the molecule. DLS and SEC results indicated the absence of aggregation formation. EC50 value of the ABD-GCSF in proliferation of NFS-60 cells was 75.76\u00a0pg\/ml after 72\u00a0h in comparison with control GCSF molecules (Filgrastim: 73.1\u00a0pg\/ml and PEG-Filgrastim: 44.6\u00a0pg\/ml). Animal studies of ABD-GCSF represented improved serum half-life (9.3\u2009\u00b1\u20090.7\u00a0h) and consequently reduced renal clearance (16.1\u2009\u00b1\u20091.4\u00a0ml\/h.kg) in comparison with Filgrastim (1.7\u2009\u00b1\u20090.1\u00a0h). Enhanced neutrophils count following administration of ABD-GCSF was comparable with Filgrastim and weaker than PEG-Filgrastim treated rats. In vitro and in vivo results suggested the ABD fusion as a potential approach for improving GCSF properties.<\/jats:p>","DOI":"10.1038\/s41598-021-04560-6","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T11:03:33Z","timestamp":1642071813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Extension of human GCSF serum half-life by the fusion of albumin binding domain"],"prefix":"10.1038","volume":"12","author":[{"given":"Fatemeh Yadavar","family":"Nikravesh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira","family":"Shirkhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Bayat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeganeh","family":"Talebkhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esmat","family":"Mirabzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoumeh","family":"Sabzalinejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hooman Aghamirza Moghim","family":"Aliabadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Nematollahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalda Hosseinzadeh","family":"Ardakani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soroush","family":"Sardari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"4560_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.cyto.2008.03.002","volume":"42","author":"AD Panopoulos","year":"2008","unstructured":"Panopoulos, A. D. & Watowich, S. S. Granulocyte colony-stimulating factor: Molecular mechanisms of action during steady state and \u2018emergency\u2019 hematopoiesis. Cytokine 42, 277\u2013288 (2008).","journal-title":"Cytokine"},{"key":"4560_CR2","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.4161\/cc.4.12.2213","volume":"4","author":"A Schneider","year":"2005","unstructured":"Schneider, A., Kuhn, H. G. & Sch\u00e4bitz, W. R. A role for G-CSF (Granulocyte-colony stimulating factor) in the central nervous system. Cell Cycle 4, 1753\u20131757 (2005).","journal-title":"Cell Cycle"},{"key":"4560_CR3","first-page":"1","volume":"2013","author":"S Zhao","year":"2013","unstructured":"Zhao, S. et al. Extending the serum half-life of G-CSF via fusion with the domain III of human serum albumin. Biomed. Res. Int. 2013, 1\u20138 (2013).","journal-title":"Biomed. Res. Int."},{"key":"4560_CR4","first-page":"285","volume":"49","author":"K Tiwari","year":"2012","unstructured":"Tiwari, K. et al. Refolding of recombinant human granulocyte colony stimulating factor: Effect of cysteine\/cystine redox system. Indian. J. Biochem. Biophys. 49, 285\u2013288 (2012).","journal-title":"Indian. J. Biochem. Biophys."},{"key":"4560_CR5","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1161\/01.STR.0000208205.26253.96","volume":"37","author":"I Solaroglu","year":"2006","unstructured":"Solaroglu, I., Cahill, J., Jadhav, V. & Zhang, J. H. A novel neuroprotectant granulocyte-colony stimulating factor. Stroke 37, 1123\u20131128 (2006).","journal-title":"Stroke"},{"key":"4560_CR6","unstructured":"O-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity"},{"key":"4560_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1475-2859-7-13","volume":"7","author":"AL Vanz","year":"2008","unstructured":"Vanz, A. L. et al. Human granulocyte colony stimulating factor (hG-CSF): Cloning, overexpression, purification and characterization. Microb. Cell Fact. 7, 13 (2008).","journal-title":"Microb. Cell Fact."},{"key":"4560_CR8","first-page":"3","volume":"10","author":"S Basu","year":"2002","unstructured":"Basu, S., Dunn, A. & Ward, A. G-CSF: Function and modes of action (Review). Int. J. Mol. Med. 10, 3\u201310 (2002).","journal-title":"Int. J. Mol. Med."},{"key":"4560_CR9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ejpb.2009.12.002","volume":"74","author":"Y-S Huang","year":"2010","unstructured":"Huang, Y.-S. et al. Engineering a pharmacologically superior form of granulocyte-colony-stimulating factor by fusion with gelatin-like-protein polymer. Eur. J. Pharm. Biopharm. 74, 435\u2013441 (2010).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"4560_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40259-015-0133-6","volume":"29","author":"WR Strohl","year":"2015","unstructured":"Strohl, W. R. Fusion proteins for half-life extension of biologics as a strategy to make biobetters. BioDrugs 29, 215\u2013239 (2015).","journal-title":"BioDrugs"},{"key":"4560_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jconrel.2015.10.038","volume":"240","author":"VN Podust","year":"2016","unstructured":"Podust, V. N. et al. Extension of in vivo half-life of biologically active molecules by XTEN protein polymers. J. Control. Release. 240, 52\u201366 (2016).","journal-title":"J. Control. Release."},{"key":"4560_CR12","doi-asserted-by":"publisher","first-page":"6480","DOI":"10.1038\/s41598-017-06726-7","volume":"7","author":"BH Do","year":"2017","unstructured":"Do, B. H. et al. Granulocyte colony-stimulating factor (GCSF) fused with Fc domain produced from E. coli is less effective than Polyethylene Glycol-conjugated GCSF. Sci. Rep. 7, 6480 (2017).","journal-title":"Sci. Rep."},{"key":"4560_CR13","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1080\/10826068.2016.1252922","volume":"47","author":"M Sigar","year":"2017","unstructured":"Sigar, M., Maity, N. & Mishra, S. Enhancing granulocyte colony-stimulating factor expression in Pichia pastoris through fusion with human serum albumin. Prep. Biochem. Biotechnol. 47, 364\u2013370 (2017).","journal-title":"Prep. Biochem. Biotechnol."},{"key":"4560_CR14","doi-asserted-by":"publisher","first-page":"8114","DOI":"10.1074\/jbc.M109943200","volume":"277","author":"MU Johansson","year":"2002","unstructured":"Johansson, M. U. et al. Structure, specificity, and mode of interaction for bacterial albumin-binding modules. J. Biol. Chem. 277, 8114\u20138120 (2002).","journal-title":"J. Biol. Chem."},{"key":"4560_CR15","doi-asserted-by":"publisher","first-page":"120073","DOI":"10.1016\/j.biomaterials.2020.120073","volume":"250","author":"J Guo","year":"2020","unstructured":"Guo, J., Sun, J., Liu, X., Wang, Z. & Gao, W. Head-to-tail macrocyclization of albumin-binding domain fused interferon alpha improves the stability, activity, tumor penetration, and pharmacology. Biomaterials 250, 120073 (2020).","journal-title":"Biomaterials"},{"key":"4560_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/protein\/gzv040","volume":"28","author":"SA Jacobs","year":"2015","unstructured":"Jacobs, S. A. et al. Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics. Protein. Eng. Des. Sel. 28, 385\u2013393 (2015).","journal-title":"Protein. Eng. Des. Sel."},{"key":"4560_CR17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/protein\/gzt023","volume":"26","author":"M Schlapschy","year":"2013","unstructured":"Schlapschy, M. et al. PASylation: A biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins. Protein. Eng. Des. Sel. 26, 489\u2013501 (2013).","journal-title":"Protein. Eng. Des. Sel."},{"key":"4560_CR18","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1021\/acsmedchemlett.8b00226","volume":"9","author":"EM Bech","year":"2018","unstructured":"Bech, E. M., Pedersen, S. L. & Jensen, K. J. Chemical strategies for half-life extension of biopharmaceuticals: lipidation and its alternatives. ACS. Med. Chem. Lett. 9, 577\u2013580 (2018).","journal-title":"ACS. Med. Chem. Lett."},{"key":"4560_CR19","unstructured":"Moman, R. N., Gupta, N. & Varacallo, M. Physiology, Albumin. StatPearls [Internet] (2021)."},{"key":"4560_CR20","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.1021\/bi052628y","volume":"45","author":"C Chaudhury","year":"2006","unstructured":"Chaudhury, C., Brooks, C. L., Carter, D. C., Robinson, J. M. & Anderson, C. L. Albumin binding to FcRn: Distinct from the FcRn-IgG interaction. Biochemistry 45, 4983\u20134990 (2006).","journal-title":"Biochemistry"},{"key":"4560_CR21","first-page":"682","volume":"5","author":"KMK Sand","year":"2014","unstructured":"Sand, K. M. K. et al. Unraveling the interaction between FcRn and albumin: Opportunities for design of albumin-based therapeutics. Front. Immunol. 5, 682 (2014).","journal-title":"Front. Immunol."},{"key":"4560_CR22","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.ijpharm.2016.07.046","volume":"511","author":"R Guo","year":"2016","unstructured":"Guo, R. et al. Fusion of an albumin-binding domain extends the half-life of immunotoxins. Int. J. Pharm. 511, 538\u2013549 (2016).","journal-title":"Int. J. Pharm."},{"key":"4560_CR23","first-page":"851","volume":"43","author":"W Sheng","year":"2020","unstructured":"Sheng, W. et al. An albumin-binding domain and targeting peptide-based recombinant protein and its enediyne-integrated analogue exhibit directional delivery and potent inhibitory activity on pancreatic cancer with K-ras mutation. Oncol. Rep. 43, 851\u2013863 (2020).","journal-title":"Oncol. Rep."},{"key":"4560_CR24","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/protein\/gzm061","volume":"20","author":"R Stork","year":"2007","unstructured":"Stork, R., M\u00fcller, D. & Kontermann, R. E. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. Protein. Eng. Des. Sel. 20, 569\u2013576 (2007).","journal-title":"Protein. Eng. Des. Sel."},{"key":"4560_CR25","doi-asserted-by":"publisher","first-page":"e87704","DOI":"10.1371\/journal.pone.0087704","volume":"9","author":"OE Levy","year":"2014","unstructured":"Levy, O. E. et al. Novel exenatide analogs with peptidic albumin binding domains: Potent anti-diabetic agents with extended duration of action. PLoS ONE 9, e87704 (2014).","journal-title":"PLoS ONE"},{"key":"4560_CR26","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/1574-6976.12005","volume":"37","author":"EC Murphy","year":"2013","unstructured":"Murphy, E. C. & Frick, I.-M. Gram-positive anaerobic cocci\u2013commensals and opportunistic pathogens. FEMS. Microbiol. Rev. 37, 520\u2013553 (2013).","journal-title":"FEMS. Microbiol. Rev."},{"key":"4560_CR27","doi-asserted-by":"publisher","first-page":"e201303009","DOI":"10.5936\/csbj.201303009","volume":"6","author":"J Nilvebrant","year":"2013","unstructured":"Nilvebrant, J. & Hober, S. The albumin-binding domain as a scaffold for protein engineering. Comput. Struct. Biotechnol. J. 6, e201303009 (2013).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"4560_CR28","doi-asserted-by":"publisher","first-page":"961","DOI":"10.2967\/jnumed.112.110700","volume":"54","author":"A Orlova","year":"2013","unstructured":"Orlova, A. et al. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein. J. Nucl. Med. 54, 961\u2013968 (2013).","journal-title":"J. Nucl. Med."},{"key":"4560_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/605427","volume":"2015","author":"J Zurdo","year":"2015","unstructured":"Zurdo, J. et al. Early implementation of QbD in biopharmaceutical development: A practical example. Biomed Res. Int. 2015, 1\u201319 (2015).","journal-title":"Biomed Res. Int."},{"key":"4560_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/978-1-61779-921-1_7","volume":"899","author":"J Feldwisch","year":"2012","unstructured":"Feldwisch, J. & Tolmachev, V. Engineering of affibody molecules for therapy and diagnostics. Methods Mol. Biol. 899, 103\u2013126 (2012).","journal-title":"Methods Mol. Biol."},{"key":"4560_CR31","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s12033-017-0026-7","volume":"59","author":"G Mickiene","year":"2017","unstructured":"Mickiene, G. et al. Construction, purification, and characterization of a homodimeric granulocyte colony-stimulating factor. Mol. Biotechnol. 59, 374\u2013384 (2017).","journal-title":"Mol. Biotechnol."},{"key":"4560_CR32","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.4049\/jimmunol.1500861","volume":"195","author":"HM Mehta","year":"2015","unstructured":"Mehta, H. M., Malandra, M. & Corey, S. J. G-CSF and GM-CSF in neutropenia. J. Immunol. 195, 1341\u20131349 (2015).","journal-title":"J. Immunol."},{"key":"4560_CR33","doi-asserted-by":"publisher","first-page":"9S","DOI":"10.1592\/phco.23.9.9S.32888","volume":"23","author":"WC Zamboni","year":"2003","unstructured":"Zamboni, W. C. Pharmacokinetics of pegfilgrastim. Pharmacotherapy 23, 9S-14S (2003).","journal-title":"Pharmacotherapy"},{"key":"4560_CR34","doi-asserted-by":"crossref","unstructured":"Molineux, G. Pegfilgrastim: designing an improved form of rmetHuG-CSF in PEGylated Protein Drugs: Basic Science and Clinical Applications (ed. Veronese, FM) 169\u2013185 (2009).","DOI":"10.1007\/978-3-7643-8679-5_10"},{"key":"4560_CR35","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/978-1-60761-913-0_17","volume":"681","author":"ST Loughran","year":"2011","unstructured":"Loughran, S. T. & Walls, D. Purification of poly-histidine-tagged proteins. Methods Mol. Biol. 681, 311\u2013335 (2011).","journal-title":"Methods Mol. Biol."},{"key":"4560_CR36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.pep.2003.10.010","volume":"33","author":"AK Mohanty","year":"2004","unstructured":"Mohanty, A. K. & Wiener, M. C. Membrane protein expression and production: Effects of polyhistidine tag length and position. Protein Expr. Purif. 33, 311\u2013325 (2004).","journal-title":"Protein Expr. Purif."},{"key":"4560_CR37","doi-asserted-by":"crossref","unstructured":"Rosano, G. L. & Ceccarelli, E. A. Recombinant protein expression in Escherichia coli: Advances and challenges. Front. Microbiol. 5, (2014).","DOI":"10.3389\/fmicb.2014.00172"},{"key":"4560_CR38","doi-asserted-by":"publisher","first-page":"953","DOI":"10.4014\/jmb.1412.12079","volume":"25","author":"MN Baeshen","year":"2015","unstructured":"Baeshen, M. N. et al. Production of biopharmaceuticals in E. coli: Current scenario and future perspectives. J. Microbiol. Biotechnol. 25, 953\u2013962 (2015).","journal-title":"J. Microbiol. Biotechnol."},{"key":"4560_CR39","doi-asserted-by":"publisher","first-page":"346","DOI":"10.14737\/journal.aavs\/2016\/4.7.346.356","volume":"4","author":"AR Gomes","year":"2016","unstructured":"Gomes, A. R., Byregowda, S. M., Veeregowda, B. M. & Balamurugan, V. An overview of heterologous expression host systems for the production of recombinant proteins. Adv. Anim. Vet. Sci. 4, 346\u2013356 (2016).","journal-title":"Adv. Anim. Vet. Sci."},{"key":"4560_CR40","doi-asserted-by":"publisher","first-page":"22518","DOI":"10.3390\/ijms151222518","volume":"15","author":"A Ghisaidoobe","year":"2014","unstructured":"Ghisaidoobe, A. & Chung, S. Intrinsic Tryptophan Fluorescence in the detection and analysis of proteins: A focus on f\u00f6rster resonance energy transfer techniques. Int. J. Mol. Sci. 15, 22518\u201322538 (2014).","journal-title":"Int. J. Mol. Sci."},{"key":"4560_CR41","doi-asserted-by":"publisher","first-page":"6545","DOI":"10.1039\/C6PY01616B","volume":"7","author":"A Mero","year":"2016","unstructured":"Mero, A. et al. Site-selective enzymatic chemistry for polymer conjugation to protein lysine residues: PEGylation of G-CSF at lysine-41. Polym. Chem. 7, 6545\u20136553 (2016).","journal-title":"Polym. Chem."},{"key":"4560_CR42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.pep.2017.07.006","volume":"139","author":"L Xu","year":"2017","unstructured":"Xu, L. et al. Purification and characterization of a long-acting ciliary neurotrophic factor via genetically fused with an albumin-binding domain. Protein. Expr. Purif. 139, 14\u201320 (2017).","journal-title":"Protein. Expr. Purif."},{"key":"4560_CR43","doi-asserted-by":"publisher","first-page":"7292","DOI":"10.1073\/pnas.0500062102","volume":"102","author":"Y Bai","year":"2005","unstructured":"Bai, Y., Ann, D. K. & Shen, W.-C. Recombinant granulocyte colony-stimulating factor-transferrin fusion protein as an oral myelopoietic agent. Proc. Natl. Acad. Sci. U.S.A. 102, 7292\u20137296 (2005).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"4560_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jim.2014.10.005","volume":"416","author":"M Wadhwa","year":"2015","unstructured":"Wadhwa, M. et al. Establishment of the first international standard for PEGylated granulocyte colony stimulating factor (PEG-G-CSF): Report of an international collaborative study. J. Immunol. Methods. 416, 17\u201328 (2015).","journal-title":"J. Immunol. Methods."},{"key":"4560_CR45","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1248\/bpb.b13-00132","volume":"36","author":"JS Kang","year":"2013","unstructured":"Kang, J. S. & Lee, K. C. In vivo pharmacokinetics and pharmacodynamics of positional isomers of mono-PEGylated recombinant human granulocyte colony stimulating factor in rats. Biol. Pharm. Bull. 36, 1146\u20131151 (2013).","journal-title":"Biol. Pharm. Bull."},{"key":"4560_CR46","first-page":"1535","volume":"271","author":"T Kuwabara","year":"1994","unstructured":"Kuwabara, T., Kato, Y., Kobayashi, S. & No, Y. S. Nonlinear pharmacokinetics of a recombinant human granulocyte colony-stimulating factor derivative (nartograstim): Species differences among rats, monkeys and humans. J. Pharmacol. Exp. Ther. 271, 1535\u20131543 (1994).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"4560_CR47","first-page":"1313","volume":"25","author":"SG Ericson","year":"1997","unstructured":"Ericson, S. G., Gao, H., Gericke, G. H. & Lewis, L. D. The role of polymorphonuclear neutrophils (PMNs) in clearance of granulocyte colony-stimulating factor (G-CSF) in vivo and in vitro. Exp. Hematol. 25, 1313\u20131325 (1997).","journal-title":"Exp. Hematol."},{"key":"4560_CR48","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0928-0987(00)00219-0","volume":"13","author":"N Hayashi","year":"2001","unstructured":"Hayashi, N. et al. Estimation of rhG-CSF absorption kinetics after subcutaneous administration using a modified Wagner-Nelson method with a nonlinear elimination model. Eur. J. Pharm. Sci. 13, 151\u2013158 (2001).","journal-title":"Eur. J. Pharm. Sci."},{"key":"4560_CR49","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1023\/A:1015880819328","volume":"7","author":"A Supersaxo","year":"1990","unstructured":"Supersaxo, A., Hein, W. R. & Steffen, H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm. Res. 7, 167\u2013169 (1990).","journal-title":"Pharm. Res."},{"key":"4560_CR50","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1208\/s12248-012-9367-0","volume":"14","author":"WF Richter","year":"2012","unstructured":"Richter, W. F., Bhansali, S. G. & Morris, M. E. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J. 14, 559\u2013570 (2012).","journal-title":"AAPS J."},{"key":"4560_CR51","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2165\/11586040-000000000-00000","volume":"50","author":"B-B Yang","year":"2011","unstructured":"Yang, B.-B. & Kido, A. Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin. Pharmacokinet. 50, 295\u2013306 (2011).","journal-title":"Clin. Pharmacokinet."},{"key":"4560_CR52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1128\/AAC.43.1.21","volume":"43","author":"K Terashi","year":"1999","unstructured":"Terashi, K. et al. Close association between clearance of recombinant human granulocyte colony-stimulating factor (G-CSF) and G-CSF receptor on neutrophils in cancer patients. Antimicrob. Agents Chemother. 43, 21\u201324 (1999).","journal-title":"Antimicrob. Agents Chemother."},{"key":"4560_CR53","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/ajh.10434","volume":"74","author":"MG Hunter","year":"2003","unstructured":"Hunter, M. G., Druhan, L. J., Massullo, P. R. & Avalos, B. R. Proteolytic cleavage of granulocyte colony-stimulating factor and its receptor by neutrophil elastase induces growth inhibition and decreased cell surface expression of the granulocyte colony-stimulating factor receptor. Am. J. Hematol. 74, 149\u2013155 (2003).","journal-title":"Am. J. Hematol."},{"key":"4560_CR54","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3109\/03602539608994020","volume":"28","author":"T Kuwabara","year":"1996","unstructured":"Kuwabara, T., Kobayashi, S. & Sugiyama, Y. Pharmacokinetics and pharmacodynamics of a recombinant human granulocyte colony-stimulating factor. Drug Metab. Rev. 28, 625\u2013658 (1996).","journal-title":"Drug Metab. Rev."},{"key":"4560_CR55","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.phrs.2003.12.011","volume":"50","author":"AC Kotto-Kome","year":"2004","unstructured":"Kotto-Kome, A. C. et al. Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharmacol. Res. 50, 55\u201358 (2004).","journal-title":"Pharmacol. Res."},{"key":"4560_CR56","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1080\/1042819031000103953","volume":"44","author":"A Grigg","year":"2003","unstructured":"Grigg, A. et al. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin\u2019s lymphoma. Leuk. Lymphoma 44, 1503\u20131508 (2003).","journal-title":"Leuk. Lymphoma"},{"key":"4560_CR57","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/annonc\/mdf130","volume":"13","author":"FA Holmes","year":"2002","unstructured":"Holmes, F. A. et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim inchemotherapy-induced neutropenia: A multicenterdose-finding study in women with breast cancer. Ann. Oncol. 13, 903\u2013909 (2002).","journal-title":"Ann. Oncol."},{"key":"4560_CR58","doi-asserted-by":"publisher","first-page":"77","DOI":"10.18869\/acadpub.ibj.21.2.77","volume":"21","author":"E Adabi","year":"2017","unstructured":"Adabi, E., Saebi, F., Moradi Hasan-Abad, A., Teimoori-Toolabi, L. & Kardar, G. A. Evaluation of an albumin-binding domain protein fused to recombinant human IL-2 and its effects on the bioactivity and serum half-life of the cytokine. Iran. Biomed. J. 21, 77\u201383 (2017).","journal-title":"Iran. Biomed. J."},{"key":"4560_CR59","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1021\/acs.molpharmaceut.7b00497","volume":"14","author":"L Liu","year":"2017","unstructured":"Liu, L. et al. Albumin binding domain fusing R\/K-X-X-R\/K sequence for enhancing tumor delivery of doxorubicin. Mol. Pharm. 14, 3739\u20133749 (2017).","journal-title":"Mol. Pharm."},{"key":"4560_CR60","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.3389\/fphar.2021.759337","volume":"12","author":"M Siegemund","year":"2021","unstructured":"Siegemund, M. et al. Pharmacokinetic engineering of OX40-blocking anticalin proteins using monomeric plasma half-life extension domains. Front. Pharmacol. 12, 2865 (2021).","journal-title":"Front. Pharmacol."},{"key":"4560_CR61","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jconrel.2016.03.004","volume":"228","author":"R Li","year":"2016","unstructured":"Li, R. et al. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL. J. Control. Release 228, 96\u2013106 (2016).","journal-title":"J. Control. Release"},{"key":"4560_CR62","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1111\/bph.15193","volume":"177","author":"NP du Sert","year":"2020","unstructured":"du Sert, N. P. et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. Br. J. Pharmacol. 177, 3617\u20133624 (2020).","journal-title":"Br. J. Pharmacol."},{"key":"4560_CR63","doi-asserted-by":"publisher","first-page":"e91990","DOI":"10.1371\/journal.pone.0091990","volume":"9","author":"GN Cox","year":"2014","unstructured":"Cox, G. N. et al. Hematopoietic properties of granulocyte colony-stimulating factor\/immunoglobulin (G-CSF\/IgG-Fc) fusion proteins in normal and neutropenic rodents. PLoS ONE 9, e91990 (2014).","journal-title":"PLoS ONE"},{"key":"4560_CR64","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jconrel.2012.02.025","volume":"159","author":"A Mero","year":"2012","unstructured":"Mero, A., Fang, Z., Pasut, G., Veronese, F. M. & Viegas, T. X. Selective conjugation of poly(2-ethyl 2-oxazoline) to granulocyte colony stimulating factor. J. Control. Release 159, 353\u2013361 (2012).","journal-title":"J. Control. Release"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04560-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04560-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04560-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T20:53:17Z","timestamp":1669323197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04560-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4560"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-04560-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,13]]},"assertion":[{"value":"24 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"667"}}